Imaging biomarkers associated with extra-axial intracranial tumors: a systematic review

Abstract

Extra-axial brain tumors are extra-cerebral tumors and are usually benign. The choice of treatment for extra-axial tumors is often dependent on the growth of the tumor, and imaging plays a significant role in monitoring growth and clinical decision-making. This motivates the investigation of imaging biomarkers for these tumors that may be incorporated into clinical workflows to inform treatment decisions. The databases from Pubmed, Web of Science, Embase, and Medline were searched from 1 January 2000 to 7 March 2022, to systematically identify relevant publications in this area. All studies that used an imaging tool and found an association with a growth-related factor, including molecular markers, grade, survival, growth/progression, recurrence, and treatment outcomes, were included in this review. We included 42 studies, comprising 22 studies (50%) of patients with meningioma; 17 studies (38.6%) of patients with pituitary tumors; three studies (6.8%) of patients with vestibular schwannomas; and two studies (4.5%) of patients with solitary fibrous tumors. The included studies were explicitly and narratively analyzed according to tumor type and imaging tool. The risk of bias and concerns regarding applicability were assessed using QUADAS-2. Most studies (41/44) used statistics-based analysis methods, and a small number of studies (3/44) used machine learning. Our review highlights an opportunity for future work to focus on machine learning-based deep feature identification as biomarkers, combining various feature classes such as size, shape, and intensity. Systematic Review Registration: PROSPERO, CRD42022306922.

Keywords: biomarker; extra-axial; growth; imaging; intracranial; marker; tumor neoplasms.

Figure 1

PRISMA flow diagram for the article selection.

Figure 2

Summary of the QUADAS-2 assessments of the included studies. (A) Graphical representation of included studies (in percentages) in each key domain in terms of the risk of bias. (B) A graphical representation of the included studies (in percentages) in each key domain in terms of the concerns regarding their applicability. (C) A tabular representation of the assessments assigned for each included study. QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies-2.